- Home
- KPRX vs CYCC Comparison
KPRX vs CYCC Comparison
Compare KPRX & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- CYCC
- Stock Information
- Founded
- KPRX 1998
- CYCC 1992
- Country
- KPRX United States
- CYCC Malaysia
- Employees
- KPRX N/A
- CYCC 12
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- CYCC Health Care
- Exchange
- KPRX Nasdaq
- CYCC Nasdaq
- Market Cap
- KPRX 9.1M
- CYCC 8.3M
- IPO Year
- KPRX N/A
- CYCC N/A
- Fundamental
- Price
- KPRX $2.82
- CYCC $0.34
- Analyst Decision
- KPRX Strong Buy
- CYCC
- Analyst Count
- KPRX 1
- CYCC 0
- Target Price
- KPRX $10.00
- CYCC N/A
- AVG Volume (30 Days)
- KPRX 1.4M
- CYCC 3.9M
- Earning Date
- KPRX 08-08-2025
- CYCC 08-13-2025
- Dividend Yield
- KPRX N/A
- CYCC N/A
- EPS Growth
- KPRX N/A
- CYCC N/A
- EPS
- KPRX N/A
- CYCC N/A
- Revenue
- KPRX $20,000.00
- CYCC $14,000.00
- Revenue This Year
- KPRX N/A
- CYCC $137.21
- Revenue Next Year
- KPRX N/A
- CYCC N/A
- P/E Ratio
- KPRX N/A
- CYCC N/A
- Revenue Growth
- KPRX N/A
- CYCC N/A
- 52 Week Low
- KPRX $2.51
- CYCC $0.25
- 52 Week High
- KPRX $4.86
- CYCC $39.84
- Technical
- Relative Strength Index (RSI)
- KPRX 40.86
- CYCC 26.19
- Support Level
- KPRX $2.87
- CYCC $0.31
- Resistance Level
- KPRX $3.22
- CYCC $0.41
- Average True Range (ATR)
- KPRX 0.18
- CYCC 0.06
- MACD
- KPRX -0.03
- CYCC 0.10
- Stochastic Oscillator
- KPRX 21.20
- CYCC 34.89
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.